A new study has examined antibody response among individuals who have received the Ebola vaccine and live in areas of the Democratic Republic of Congo (DRC) that are experiencing outbreaks of Ebola disease.
Specifically, the researchers analyzed antibody response at various time intervals following vaccination with a single dose of the Ebola vaccine in an at-risk population in the DRC.
They discovered compelling evidence of robust and persistent antibody response among vaccinated individuals in the affected areas.
The World Health Organization (WHO)Trusted Source defines the Ebola virus disease (EVD) as a “rare but severe, often fatal illness in humans.”
Its symptoms commonly include fever, fatigue, muscle pain, a sore throat, and headaches. Vomiting, diarrhea, and rashes usually follow.
In some cases, EVD symptoms include internal and external bleeding, such as bloody stool or bleeding gums.
At the moment, Ebola vaccines are one part of an important scientific strategy to overcome EVD. Alongside them are treatmentTrusted Source with medications that the Food and Drug Administration (FDA) has approved and supportive therapy, such as oral rehydration and intravenous fluids.
A collaborative study between American and Congolese scientists has recently examined the antibody response in Ebola-vaccinated individuals in the DRC, which is one of the first places where scientists discovered EVD.
